Nine viruses. One shared weakness.
In May 2026, the World Health Organization confirmed person-to-person transmission of Andes hantavirus aboard the cruise ship MV Hondius. No drug. No vaccine. Near fifty percent fatality once the lungs fill. The medical system's answer was the one it always gives: supportive care, and wait.
Salvani and Walsh argue we have been aiming at the wrong target. Every major virus - hantavirus, SARS-CoV-2, influenza, HIV, hepatitis, dengue, Ebola, RSV - survives by breaking the same machine: the cell's antioxidant defense system. Each picks the identical lock. So why build a separate ten-year, three-billion-dollar drug program for each?
Drawing on published cell biology, the authors trace the six-step ReBalU cascade in plain language, then hand the reader the whole protocol - ingredient table, the panel that maps personal vulnerability, risk-stratified dosing, and an hour-by-hour first day.
Every ingredient is GRAS. No drugs. No prescriptions.
Because there will be another outbreak.
Education only. Not medical advice.
